^
Association details:
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Title:

Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Excerpt:
...it is recommended that patients with TP53 deletion/mutation are treated with novel inhibitors (ibrutinib; idelalisib and rituximab) in front-line and relapse settings.
DOI:
10.1093/annonc/mdv303